Amaxa-Promega Partnership to Enable
Simplified Monitoring of Cell Signaling Events in Stem Cells, Cancer
Cells and Primary Cells
Cologne, Germany and Madison, WI,
USA (October 8, 2007)
Amaxa and Promega today announced an
agreement to develop applications that will provide cell biologists
broader access to monitor cell signaling events in
difficult-to-transfect cells, including stem cells, cancer cells and
primary cells. Integrating their industry leading technologies in
luminescence-based assays and transfection methodologies will
simplify transfection of reporter genes and assay development in
these difficult-to-transfect cell types.
Amaxa’s Nucleofector®
Technology enables unprecedented transfection capability and
consistent performance in applications involving more biologically
relevant mammalian systems, such as primary cells and stem cells.
“With the Nucleofector® Technology, transfection
efficiencies of up to 95% using DNA and 99% using siRNA
oligonucleotides can be achieved in difficult-to-transfect cells.
Thus, the combination of Promega’s and Amaxa’s technologies will
enable researchers to obtain much more significant results with
physiologically relevant cells rather than more artifical cell lines”
said Rainer
Christine, co-founder and CEO, Amaxa.
Introducing the Nucleofector®
96-well Shuttle® System has expanded use of the
technology to high-throughput applications such as drug screening.
Promega luciferase reporter gene
vectors and assay reagents are the most sensitive bioluminescent
tools to monitor cell signaling events and provide the widest
dynamic range in reporter assay technologies. “Luciferase reporters
are routinely used to monitor gene expression and are ideal tools
for high-throughput screening, RNAi-mediated gene regulation and
detection of cellular metabolism and viability. The combination of
Promega’s luciferase products and Amaxa’s technology will enable the
generation of stable cell lines and bioluminescent cell-based assays
even for primary cells” said John Watson, Director of Cellular
Analysis, Promega.
About Amaxa
As globally
active leader in transfection technologies, Amaxa is dedicated to
enhancing the speed and quality of basic and pharmaceutical research
in academia and industry, and aspires to make a significant
contribution to the development of causal therapies for the
treatment of severe diseases. Amaxa pursues this goal by providing
cutting edge products to the R&D and clinical markets. Founded in
1998, Amaxa is located in Cologne, Germany, and in Gaithersburg, MD,
USA. The company’s research team is one of the largest R&D groups
working on non-viral gene transfer. For more information about Amaxa,
visit
www.amaxa.com.
About
Promega
Promega
Corporation is a leader in providing innovative solutions and
technical support to the life sciences industry. The company’s 1,450
products enable scientists worldwide to advance their knowledge in
genomics, proteomics, cellular analysis, molecular diagnostics and
human identification. For more information about Promega, visit
www.promega.com.
